Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients

The National Institutes of Health, National Cancer Institute, issued an award notice for solicitation 75N91021R00007 to support the Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients program. This requirement is classified under NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN12 Health R&D Services; Health Care Services; Applied Research. Alexis Hudak is the primary point of contact for this award, which involves performance at various locations across the United States.

The agency established a Multiple-Award Indefinite Delivery, Indefinite Quantity contract with three organizations to conduct these preclinical evaluations. The University of Pittsburgh, based in Pittsburgh, Pennsylvania, received contract 75N91021D00019 on September 24, 2021. The Mayo Clinic in Rochester, Minnesota, was awarded contract 75N91021D00020 on September 23, 2021, and SRI International in Menlo Park, California, was awarded contract 75N91021D00021 on the same date. These contracts facilitate specialized research and development services necessary for evaluating pharmacological agents intended for cancer treatment.